Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?

Background In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The...

Full description

Saved in:
Bibliographic Details
Published in:EJNMMI radiopharmacy and chemistry 2023-10, Vol.8 (1), p.27-27, Article 27
Main Authors: Radzina, Maija, Saule, Laura, Mamis, Edgars, Koester, Ulli, Cocolios, Thomas Elias, Pajuste, Elina, Kalnina, Marika, Palskis, Kristaps, Sawitzki, Zoe, Talip, Zeynep, Jensen, Mikael, Duchemin, Charlotte, Leufgen, Kirsten, Stora, Thierry
Format: Article
Language:English
Subjects:
Consortia
Diagnostic
Emitters
End users
Imaging
Isotopes
Medicine
Medicine & Public Health
Molecular Medicine
Nuclear Chemistry
Nuclear Medicine
PET/CT
Pharmacotherapy
PRISMAP programme
Professional associations
Questionnaires
Radioisotopes
Radiology
Radionuclides
Review
Terbium
Terbium isotopes
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. Main body A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177 Lu, 68  Ga, 111 In, 90 Y, other alpha emitters, 225 Ac, 64 Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2–5 years are 64 Cu, Terbium radionuclide “family” and alpha emitters, such as 225 Ac. Conclusions Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.
ISSN:2365-421X
2365-421X
DOI:10.1186/s41181-023-00211-5